What if you invested $1000 in DHR on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Danaher Corporation has delivered an average annual return of 18.9%. The stock peaked in 2016 with a massive +75.3% gain, while investors faced a downturn in 2008 (-34.2%). Overall, the stock finished in the green 15 times out of 20 years.
Avg Return
+18.9%
Win Rate
75%
15W - 5L
Best
+75.3%
2016
Worst
-34.2%
2008
Performance Consistency
About Danaher Corporation
Visit Website ↗Danaher Corporation is an American healthcare company specializing in developing products for advancements in biotechnology, life sciences, and diagnostics. The company operates through three main divisions: biotechnology, life sciences, and diagnostics, providing innovative solutions to global health challenges.
Key Business Segments
Biotechnology
Provides a wide range of tools and consumables for biopharmaceutical research, development, and manufacturing through brands like Cytiva and Pall.
Life Sciences
Offers instruments, consumables, and software to global customers in academic, pharmaceutical, biotechnology, and clinical research.
Diagnostics
Provides diagnostic instruments, reagents, consumables, and software to hospitals, laboratories, and other healthcare providers.
Key Innovations
- ✓Developed the Danaher Business System (DBS), a proprietary management system focused on lean manufacturing, continuous improvement, and talent development, which has been central to its success and growth.
- ✓Strategically shifted its focus towards the high-growth healthcare market through a series of significant acquisitions and divestitures.
Historical Milestones
Danaher Corporation is established by brothers Steven and Mitchell Rales, initially focusing on industrial manufacturing acquisitions.
Danaher acquires Beckman Coulter, significantly expanding its diagnostics portfolio.
Danaher spins off its industrial businesses into Fortive, sharpening its focus on life sciences and diagnostics.
Danaher acquires the biopharma business of General Electric, rebranded as Cytiva, for $21.4 billion.
Its Environmental & Applied Solutions segment is spun off into Veralto, further refining its business portfolio.